🇺🇸 FDA

Company profile · Sponsor

Servier

Servier Laboratories (Aust.) Pty.

EE4D21C · TGA pharma AU
Pipeline
1
Drugs
7
Patents
0

Quick answer

Servier (EE4D21C) is a pharma company. headquartered in AU. listed on TGA. NovaPharmaNews links 1 pipeline program, 7 drugs, and 0 patents to this profile..

Company facts

Ticker EE4D21C
Exchange TGA
Company type pharma
Headquarters AU

Pipeline (1)

Search pipeline →

  1. S 55746

    Servier

    Chronic Lymphocytic Leukaemia (CLL)

    phase 1 small molecule completed

    1 trial

Drugs (7)

Search drugs →

  1. gliclazide

    APX-GLICLAZIDE

  2. ivabradine

    APO-IVABRADINE

    ORAL approved

    C01EB17

  3. ivosidenib

    TIBSOVO

    ORAL approved

    L01XM02

  4. perindopril

    PERISYL

  5. perindopril + indapamide

    COVERSYL PLUS LD 2.5MG/0.625MG

  6. risperidone

    APO-RISPERIDONE

    INTRAMUSCULAR approved

    N05AX08

  7. trifluridine + tipiracil

    LONSURF 15/6.14

Frequently asked questions

What is Servier?

Servier (EE4D21C) is a pharma company. headquartered in AU. listed on TGA. NovaPharmaNews links 1 pipeline program, 7 drugs, and 0 patents to this profile..

What pipeline programs does Servier sponsor?

We track 1 ClinicalTrials.gov-linked program for Servier, including S 55746. Open each program for phase, modality, NCT IDs, and indication details.

Where does Servier company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.